Myeloid Therapeutics

formerly CREATE Medicines

Create Medicines | In Vivo Immune Programming with RNA-CAR Therapies

Cambridge, United States · Founded 2021 · $257.0M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$257.0M
Last Round
$122.0M Series BMay 2026
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Myeloid Therapeutics (rebranded as CREATE Medicines in October 2025) was a clinical-stage biotech pioneering in vivo immune programming using mRNA-LNP technology. Its platform engineers T cells, NK cells, and myeloid cells directly inside the body, enabling repeat-dose CAR therapies without ex vivo manufacturing.

Summary

Myeloid Therapeutics is a Biotech company based in Cambridge, United States, founded in 2021. It has raised $257.0M in total across 4 rounds, most recently a $122.0M Series B round in May 2026. Investors include Newpath Management, ARCH Venture Partners and Hatteras Venture Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BMay 2026
$122.0M

Sign up to see all 4 events

Funding: Seed through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Myeloid Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/myeloid-therapeutics"><img src="https://indexed.vc/api/badge/company/myeloid-therapeutics" alt="Myeloid Therapeutics on Indexed.vc" width="260" height="76" /></a>